On May 15, 2026, Health Canada published a Notice of Intent in the Canada Gazette, Part I, launching a public consultation on potential amendments to the Industrial Hemp Regulations (“IHR”).
The consultation signals that the federal government may be preparing to significantly modernize and streamline Canada’s industrial hemp regulatory framework. The proposed direction appears aimed at reducing regulatory burden, decreasing administrative costs, and moving toward a more risk-based approach to industrial hemp oversight.
For industrial hemp cultivators, processors, importers, exporters, CBD stakeholders, and cannabis businesses operating adjacent to the hemp industry, the consultation could represent one of the most important industrial hemp regulatory developments since the implementation of the Cannabis Act.
Health Canada stated that its goal is to reform the industrial hemp control framework to “better reflect the risks it presents to public health and public safety.”
The government specifically indicated that potential amendments may:
- eliminate or reduce certain regulatory requirements
- decrease administrative burden
- reduce licensing and permit obligations
- lower compliance costs for regulated parties
- maintain key control measures where necessary
The overall policy direction appears focused on “right-sizing” regulation for industrial hemp.
Current Industrial Hemp Framework in Canada
Industrial hemp remains regulated under the Cannabis Act and the Industrial Hemp Regulations.
Under the current framework, industrial hemp is defined as cannabis with a THC concentration of 0.3% or less in the flowering heads and leaves.
The existing IHR framework requires licences for activities including:
- cultivating industrial hemp
- selling industrial hemp
- importing or exporting seed or grain
- cleaning or preparing seed
- processing grain
- plant breeding and propagation activities
Licence holders are also subject to:
- THC testing requirements
- approved cultivar restrictions
- import/export permitting requirements
- reporting obligations
- shipment documentation requirements
Importantly, activities involving cannabinoid extraction — including extraction of CBD from industrial hemp — generally still require cannabis processing licences under the Cannabis Regulations.
Health Canada Acknowledges Industrial Hemp Carries Lower Risk
One of the more notable aspects of the Notice of Intent is Health Canada’s explicit acknowledgement that industrial hemp presents materially lower risks than cannabis.
The Notice states that industrial hemp has “a lower potential for public health harms and misuse and fewer public safety concerns” because of its low THC levels.
The government also acknowledged industry concerns that industrial hemp should be treated more like an agricultural commodity rather than regulated similarly to intoxicating cannabis products.
This language may signal a meaningful policy shift in how industrial hemp is viewed federally.
Potential Areas of Regulatory Reform
Health Canada did not publish draft amendments. However, the Notice strongly suggests several possible areas of reform.
The consultation specifically asks stakeholders whether certain requirements should be reduced or eliminated, including requirements relating to:
- cultivation licensing
- import and export controls
- THC testing
- sales of flowering heads, leaves, and branches
- reporting obligations
The consultation also asks whether the current definition of industrial hemp should be modified.
Other possible areas of reform include:
- streamlining management of the List of Approved Cultivars (“LOAC”)
- reducing administrative reporting requirements
- simplifying permit systems
- adjusting oversight mechanisms for lower-risk hemp activities
CBD and Industrial Hemp
The consultation may be particularly relevant for businesses interested in hemp-derived cannabinoids and CBD.
Industry stakeholders have long argued that industrial hemp-derived CBD should not necessarily be regulated identically to higher-THC cannabis products.
Health Canada specifically noted that CBD is “not intoxicating.”
However, the Notice does not currently propose removing CBD extraction activities from the cannabis licensing framework. At present, extraction or concentration of phytocannabinoids from industrial hemp still generally requires a cannabis processing licence under the Cannabis Regulations.
Nevertheless, the language used in the consultation may indicate openness to future discussions regarding proportional regulation of hemp-derived cannabinoids.
Balancing Deregulation With Enforcement Concerns
Despite the emphasis on reducing regulatory burden, Health Canada made clear that some control measures will remain important.
The department specifically identified concerns relating to:
- illegal cannabis cultivation disguised as industrial hemp
- diversion into illicit markets
- maintaining distinguishability between cannabis and hemp
- international reporting obligations
As a result, complete deregulation of industrial hemp appears unlikely.
Instead, the consultation appears aimed at identifying which regulatory controls remain necessary and which may no longer be proportionate to the risks posed by industrial hemp.
Cost-Benefit Analysis Questionnaire
Health Canada also announced that it will separately circulate a voluntary cost-benefit analysis questionnaire to industrial hemp licence holders.
The information gathered may be used to support future regulatory amendments and any eventual Regulatory Impact Analysis Statement (“RIAS”).
This signals that the department is actively evaluating the economic and operational impact of potential regulatory reform.
Public Consultation Period
The Notice of Intent initiates a 45-day public consultation period ending June 30, 2026.
Health Canada is seeking feedback from:
- industrial hemp licence holders
- cannabis industry participants
- agricultural stakeholders
- processors and exporters
- researchers
- other interested parties
Stakeholders may submit comments directly to Health Canada by email.
Why This Matters
The consultation could ultimately reshape the economics and regulatory structure of Canada’s industrial hemp industry.
Potential reforms may affect:
- industrial hemp cultivation businesses
- CBD and cannabinoid businesses
- exporters and importers
- hemp processors
- agricultural producers
- cannabis licence holders operating in the hemp sector
If Health Canada proceeds with substantive amendments, the result could be a more commercially flexible and less administratively burdensome hemp framework.
At the same time, businesses should expect continued oversight relating to THC thresholds, diversion prevention, and public safety concerns.
Conclusion
Health Canada’s May 2026 Notice of Intent may represent the beginning of a significant evolution in Canada’s industrial hemp regulatory framework.
The consultation suggests that the federal government is actively considering whether current industrial hemp controls remain proportionate to the risks associated with low-THC cannabis products.
For industrial hemp businesses and cannabis stakeholders, the consultation presents an important opportunity to help shape future regulatory policy.
Substance Law advises businesses across Canada on industrial hemp regulation, cannabis licensing, CBD compliance, and Cannabis Act regulatory matters.
